$32.6 M

ONTX Mkt cap, 09-Nov-2018

$485 K

Onconova Therapeutics Revenue Q2, 2018
Onconova Therapeutics Net income (Q2, 2018)-4.3 M
Onconova Therapeutics EBIT (Q2, 2018)-5.6 M
Onconova Therapeutics Cash, 30-Jun-201829.5 M

Onconova Therapeutics Income Statement

Annual

USDFY, 2013FY, 2015FY, 2016FY, 2017

Revenue

4.8m11.5m5.5m787.0k

R&D expense

50.2m25.9m20.1m19.1m

General and administrative expense

16.8m9.5m9.2m7.4m

Operating expense total

67.0m35.4m29.2m26.5m

EBIT

(62.2m)(24.0m)(23.7m)(25.7m)

EBIT margin, %

(1309%)(209%)(427%)(3270%)

Interest expense

4.0k

Pre tax profit

(62.1m)(24.0m)(19.7m)(24.1m)

Income tax expense

435.0k16.0k14.0k13.0k

Net Income

(62.6m)(24.0m)(19.7m)(24.1m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

1.1m447.0k125.0k114.0k114.0k123.0k1.6m1.5m2.2m1.7m210.0k324.0k110.0k564.0k485.0k

R&D expense

15.3m14.2m12.9m11.9m9.5m6.5m5.3m5.8m5.6m4.0m4.9m4.6m5.1m4.6m4.1m

General and administrative expense

5.9m4.9m4.0m3.1m3.0m2.6m2.2m3.2m2.1m2.0m2.1m1.8m1.7m1.9m2.1m

Operating expense total

21.2m19.2m16.9m15.0m12.5m9.1m7.5m9.0m7.6m6.0m7.0m6.4m6.9m6.5m6.1m

EBIT

(20.1m)(18.7m)(16.8m)(14.9m)(12.3m)(9.0m)(5.9m)(7.5m)(5.4m)(4.3m)(6.8m)(6.1m)(6.8m)(5.9m)(5.6m)

EBIT margin, %

(1801%)(4191%)(13411%)(13060%)(10832%)(7282%)(362%)(510%)(240%)(261%)(3234%)(1873%)(6145%)(1046%)(1163%)

Interest expense

1.0k

Pre tax profit

(20.1m)(14.9m)

Income tax expense

432.0k

Net Income

(20.5m)(18.7m)(16.8m)(14.9m)(12.4m)(9.0m)(5.9m)(7.2m)(5.4m)(1.6m)(8.3m)(2.6m)(7.0m)(5.1m)(4.3m)

Onconova Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

60.0m43.6m19.8m21.4m4.0m

Accounts Receivable

1.5m141.8m59.0k

Inventories

4.4m3.2m1.8m

Current Assets

104.4m46.9m23.2m23.1m4.9m

PP&E

626.0k420.0k248.0k152.0k64.0k

Total Assets

105.2m47.3m23.4m23.2m5.0m

Accounts Payable

3.7m4.0m3.4m5.3m6.2m

Short-term debt

Current Liabilities

10.3m10.3m7.6m10.2m10.0m

Long-term debt

Total Debt

Total Liabilities

24.3m12.6m18.1m15.8m

Additional Paid-in Capital

311.1m317.1m328.3m342.5m350.5m

Retained Earnings

(230.9m)(294.6m)(318.6m)(338.2m)(362.3m)

Total Equity

80.9m23.6m10.8m5.1m

Financial Leverage

1.3 x2 x2.2 x4.5 x

Onconova Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(62.6m)(63.8m)(24.0m)(19.7m)(24.1m)

Depreciation and Amortization

446.0k434.0k150.0k96.0k88.0k

Accounts Receivable

(1.4m)1.5m(28.0k)

Inventories

(2.7m)1.2m1.2m

Accounts Payable

(1.8m)317.0k(606.0k)1.9m863.0k

Cash From Operating Activities

(61.4m)(57.6m)(15.8m)(23.8m)

Cash From Investing Activities

(40.6m)39.8m39.8m

Cash From Financing Activities

80.5m1.5m7.5m17.4m6.4m

Income Taxes Paid

435.0k435.0k

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(47.9m)(18.7m)(35.5m)(14.9m)(12.4m)(21.3m)(27.2m)(7.2m)(12.6m)(14.2m)(8.3m)(10.9m)(17.9m)(5.1m)(9.4m)

Depreciation and Amortization

326.0k141.0k239.0k98.0k125.0k24.0k48.0k72.0k23.0k47.0k69.0k16.0k30.0k

Accounts Receivable

(1.4m)136.0k(643.0k)600.0k(95.0k)(202.0k)(26.0k)(418.0k)(13.0k)

Inventories

1.0m

Accounts Payable

(1.1m)(408.0k)1.3m5.4m3.9m158.0k(837.0k)(125.0k)(620.0k)650.0k84.0k358.0k113.0k848.0k456.0k

Cash From Operating Activities

(44.3m)(16.2m)(30.2m)(18.3m)(26.2m)(8.6m)(11.4m)(6.1m)(11.7m)(19.1m)(5.5m)(10.1m)

Cash From Investing Activities

(40.5m)9.9m24.8m

Cash From Financing Activities

79.9m853.0k898.0k104.0k4.8m1.6m1.6m17.4m40.0k5.3m5.3m8.7m35.7m

Onconova Therapeutics Ratios

USDY, 2018

Financial Leverage

1.9 x
Report incorrect company information

Onconova Therapeutics Employee Rating

3.01 votes
Culture & Values
N/A
Work/Life Balance
N/A
Senior Management
N/A
Salary & Benefits
N/A
Career Opportunities
N/A
Source